Neuphoria Therapeutics Inc. Common Stock (NEUP) Stock Price

NEUPStock

$3.30−78.25%52W

Market Cap$17.86M

P/E—

PEG Ratio—

Div yield—

Beta0.77

NEUP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-39.84%

Price vs S&P 500 (4W)-9.73%

VGM Score45.77

P/CF (Annual)261.80x

Book Value / Share (Quarterly)$4.55

P/TBV (Annual)0.94x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)696.24%

Cash Flow / Share (Quarterly)$-2.28

Price vs S&P 500 (YTD)-26.88%

Net Profit Margin (TTM)-417.70%

EPS (TTM)$-5.00

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$-5.00

Revenue Growth (5Y)12.62%

EPS (Annual)$-3.06

ROI (Annual)-1.94%

Net Profit Margin (5Y Avg)-5187.71%

Cash / Share (Quarterly)$3.67

ROA (Last FY)-1.29%

Revenue Growth TTM (YoY)-27.00%

EBITD / Share (TTM)$-3.59

Operating Margin (TTM)-470.62%

Cash Flow / Share (Annual)$0.04

P/B Ratio0.73x

P/B Ratio (Quarterly)0.96x

Net Income / Employee (Annual)$-1,921,700

Net Interest Coverage (TTM)-2.37x

ROA (TTM)-42.22%

EPS Incl Extra (Annual)$-3.06

Current Ratio (Annual)3.56x

Quick Ratio (Quarterly)27.33x

3-Month Avg Trading Volume0.14M

52-Week Price Return-78.25%

EV / Free Cash Flow (Annual)10.43x

Revenue / Employee (TTM)$167,700

Tangible BV / Share (Quarterly)$3.78

P/S Ratio (Annual)15.21x

Asset Turnover (Annual)0.55x

52-Week High$17.19

Operating Margin (5Y Avg)-3794.34%

EPS Excl Extra (Annual)$-3.06

26-Week Price Return-29.94%

Quick Ratio (Annual)3.39x

13-Week Price Return-3.37%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)27.85x

Enterprise Value$-1.97M

Revenue / Share Growth (5Y)83.04%

Asset Turnover (TTM)0.04x

Revenue / Employee (Annual)$167,700

Pretax Margin (Annual)-1157.51%

Cash / Share (Annual)$7.18

3-Month Return Std Dev45.68%

Net Income / Employee (TTM)$-1,921,700

ROE (Last FY)-1.95%

Net Interest Coverage (Annual)-9.14x

EPS Basic Excl Extra (Annual)$-3.06

Receivables Turnover (TTM)0.76x

EV / Free Cash Flow (TTM)13.82x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-5.00

Receivables Turnover (Annual)2.60x

ROI (TTM)-55.83%

P/S Ratio (TTM)15.21x

Pretax Margin (5Y Avg)-4737.69%

Revenue / Share (Annual)$0.27

Tangible BV / Share (Annual)$7.18

Price vs S&P 500 (52W)-93.78%

Year-to-Date Return-14.95%

5-Day Price Return-0.60%

EPS Normalized (Annual)$-3.06

ROA (5Y Avg)-36.63%

Net Profit Margin (Annual)-1145.65%

Month-to-Date Return-7.30%

EBITD / Share (Annual)$-3.59

Operating Margin (Annual)-1401.08%

P/CF (TTM)32.84x

EPS Basic Excl Extra (TTM)$-5.00

P/TBV (Quarterly)1.15x

P/B Ratio (Annual)0.70x

Pretax Margin (TTM)-420.66%

Book Value / Share (Annual)$9.61

Price vs S&P 500 (13W)-6.05%

Beta0.77x

P/FCF (Annual)231.31x

Revenue / Share (TTM)$0.22

ROE (TTM)-55.91%

52-Week Low$3.19

vGradeC

gGradeC

mGradeC

vgmGradeC

NEUP Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Sep 18, 2026	-$0.56	$0.26	+145.91%(+$0.82)
Q1 2026	May 15, 2026	-$0.56	-$0.09	+83.93%(+$0.47)
Q4 2025	Feb 17, 2026	-$0.56	$0.41	+173.21%(+$0.97)
Q3 2025	Nov 14, 2025	-$1.31	-$4.41	-236.64%(-$3.10)
Q2 2025	Sep 29, 2025	-$3.83	-$5.55	-44.91%(-$1.72)

NEUP Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.13

2.17

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
NEUPNeuphoria Therapeutics Inc. Common Stock	C	C	C	15.2x	-27.0%	—	—	$3.30
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Neuphoria Therapeutics Inc. Common Stock

Neuphoria Therapeutics is a clinical-stage biotechnology company developing treatments for neuropsychiatric disorders. Its lead candidate, BNC 210, is an oral selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor in development for acute social anxiety disorder and chronic post-traumatic stress disorder. The company focuses on allosteric ion channel modulators targeting central nervous system disorders with significant unmet medical needs.